SCM
CSTL icon

Shelton Capital Management’s Castle Biosciences CSTL Stock Holding History

Shelton Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-164,008
Closed -$3.28M – 721
2025
Q1 		$3.28M Hold
164,008
– – 0.08% 191
2024
Q4 		$4.37M Hold
164,008
– – 0.11% 167
2024
Q3 		$4.68M Buy
+164,008
New +$4.17M 0.12% 160

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Shelton Capital Management's CSTL Position: Q2 2025 in Review

Shelton Capital Management sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 164,008 shares — an estimated $3.28M sold.

Shelton Capital Management first reported a position in CSTL in Q3 2024 and held it in 3 quarters. The position peaked at $4.68M in Q3 2024. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Shelton Capital Management reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Shelton Capital Management sold 164,008 Castle Biosciences shares in Q2 2025, an estimated $3.28M.
  • Shelton Capital Management first reported a position in Castle Biosciences in Q3 2024 and held it in 3 quarters.
  • Shelton Capital Management's Castle Biosciences position peaked at $4.68M in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Shelton Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.